Published in Gene Therapy Weekly, October 18th, 2001
"The Wilms tumor gene (WT1) has been suggested as a powerful parameter for molecular monitoring of minimal residual disease (MRD) in leukaemias," explained Dr. Christian Andreas Schmidt and colleagues at Humboldt University in Berlin. However, the "complex and inaccurate" methods used to determine WT1 levels have discouraged routine monitoring, they noted.
Schmidt and coworkers found that real-time, quantitative molecular monitoring of WT1 is feasible using...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.